Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) was founded in 1993, formerly known as Isotechnika Pharma Inc., and changed to its current name in October 2013. It is headquartered in Vancouver, Canada and has 33 full-time employees. It is a clinical biotechnology company. A pharmaceutical company engaged in the research, development and commercialization of autoimmune disease treatment drugs in the United States, Canada, China and Switzerland.
Aurinia Pharmaceuticals (AUPH):
Aurinia is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for diseases with unmet medical needs.
Aurinia Pharmaceuticals, Inc. is currently developing the investigational drug voclosporin, a calcineurin inhibitor, for the treatment of lupus nephritis (LN) and focal segmental glomerulosclerosis (FSGS).
In addition, Aurinia Pharmaceuticals is also advancing voclosporin ophthalmic eye drops (VOS) formulations for the treatment of dry eye (DES).
Aurinia Pharmaceuticals and Cantor Fitzgerald & Co. (Contor Fitzgerald & Co., a financial services company founded in 1945, focus on institutional equity, fixed income sales and transactions, and through investment banking services, prime brokerage and commercial Real estate financing serves the middle market. The company also actively participates in new businesses, including consulting and asset management services, game technology and e-commerce. The company has more than 5,000 institutional customers) signed a sales agreement; signed a manufacturing cooperation and service agreement with Lonza Ltd. .